Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01478178 · ClinicalTrials.gov registry record · Phase 1
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
A Phase 1 study, sponsored by Kintara Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT01478178 is a Phase 1 study that has completed, run by Kintara Therapeutics. The registered enrollment target is 55 participants.
The verdict
NCT01478178, a Phase 1 study, has completed, sponsored by Kintara Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and the maximal tolerated dose (MTD) of VAL-083 in patients with recurrent malignant glioma. Pharmacokinetic (PK) properties will be explored and tumor responses to treatment will be evaluated.
Interventions
- DRUG VAL-083 (Dianhydrogalactitol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2011-10 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01478178
The ClinicalTrials.gov registry entry for NCT01478178 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kintara Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VAL-083 (Dianhydrogalactitol) is the first listed.
NCT01478178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01478178 about?
NCT01478178 is a clinical study titled "Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma". The purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and the maximal tolerated dose (MTD) of VAL-083 in patients with recurrent malignant glioma. Pharmacokinetic (PK) properties will be explored and tumor responses to treatment will be evaluated.
What is the current status of trial NCT01478178?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2011-10. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01478178?
The interventions under investigation include: VAL-083 (Dianhydrogalactitol) (DRUG).
Who is sponsoring clinical trial NCT01478178?
This trial is sponsored by Kintara Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.